Search

Your search keyword '"Goto, Shunsuke"' showing total 563 results
Start Over Author "Goto, Shunsuke"
563 results on '"Goto, Shunsuke"'

13. Generation of coupled orbital angular momentum modes from an optical vortex parametric laser source

Author

Mamuti, Roukuya, Goto, Shunsuke, Miyamoto, Katsuhiko, and Omatsu, Takashige

Subjects
Physics - Optics, Quantum Physics
Abstract

We report on the generation of flower (wheel) modes, which manifest coupled orbital angular momentum (OAM) modes, from a vortex pumped optical parametric oscillator simply by employing a pump source with a short temporal coherence time. This vortex oscillator was also developed to generate a further higher-order vortex signal output with $l_s=2-4$ by replacement of the pump source with a longer coherence time. The signal and idler outputs were tuned within wavelength ranges of 745-955 nm and 1200-1855 nm, respectively. The maximum signal output energy of 1.2 mJ was measured with an optical efficiency of 15.6%.

Published
2019
Full Text
View/download PDF

14. Annual dialysis data report 2019, JSDT Renal Data Registry

Author

Hanafusa, Norio, Abe, Masanori, Joki, Nobuhiko, Ogawa, Tetsuya, Kanda, Eiichiro, Kikuchi, Kan, Goto, Shunsuke, Taniguchi, Masatomo, Nakai, Shigeru, Naganuma, Toshihide, Hasegawa, Takeshi, Hoshino, Junichi, Miura, Kenichiro, Wada, Atsushi, and Takemoto, Yoshiaki

Published
2023
Full Text
View/download PDF

16. Deep learning analysis of clinical course of primary nephrotic syndrome: Japan Nephrotic Syndrome Cohort Study (JNSCS)

Author

Kimura, Tomonori, Yamamoto, Ryohei, Yoshino, Mitsuaki, Sakate, Ryuichi, Imai, Enyu, Maruyama, Shoichi, Yokoyama, Hitoshi, Sugiyama, Hitoshi, Nitta, Kosaku, Tsukamoto, Tatsuo, Uchida, Shunya, Takeda, Asami, Sato, Toshinobu, Wada, Takashi, Hayashi, Hiroki, Akai, Yasuhiro, Fukunaga, Megumu, Tsuruya, Kazuhiko, Masutani, Kosuke, Konta, Tsuneo, Shoji, Tatsuya, Hiramatsu, Takeyuki, Goto, Shunsuke, Tamai, Hirofumi, Nishio, Saori, Nagai, Kojiro, Yamagata, Kunihiro, Yasuda, Hideo, Ichida, Shizunori, Naruse, Tomohiko, Nishino, Tomoya, Sobajima, Hiroshi, Akahori, Toshiyuki, Ito, Takafumi, Terada, Yoshio, Katafuchi, Ritsuko, Fujimoto, Shouichi, Okada, Hirokazu, Mimura, Tetsushi, Suzuki, Satoshi, Saka, Yosuke, Sofue, Tadashi, Kitagawa, Kiyoki, Fujita, Yoshiro, Mizutani, Makoto, Kashihara, Naoki, Sato, Hiroshi, Narita, Ichiei, and Isaka, Yoshitaka

Published
2022
Full Text
View/download PDF

18. Patient characteristics modify the association between changes in mineral metabolism parameters and mortality in a nationwide hemodialysis cohort study.

Author

Goto, Shunsuke, Hamano, Takayuki, Taniguchi, Masatomo, Abe, Masanori, Nitta, Kosaku, Nishi, Shinichi, and Fujii, Hideki

Abstract

In hemodialysis patients, it remains unclear whether patient characteristics influence the clinical impacts of changes in serum mineral metabolism parameters on mortality. In this 9-year cohort study, we investigated the associations between the changes in calcium/phosphate levels and all-cause mortality using a time-dependent approach after adjustment for potential confounders in groups stratified by performance status (PS), a history of atherosclerotic cardiovascular disease (ACVD), or diabetic nephropathy (DN). In patients with baseline serum calcium levels of 9.5–<10.0 mg/dL, increases in serum calcium levels were associated with higher mortality exclusively in patients with PS Grade 0. In the same baseline calcium range, a significant association was observed between reduced serum calcium levels and lower mortality only in patients with a history of ACVD or DN. Similarly, in patients with baseline serum phosphate levels of 5.0–<5.5 mg/dL, reduced serum phosphate levels were associated with lower mortality only in those with PS Grade 0, a history of ACVD or DN. These findings indicate that PS should be considered in treating mild hypercalcemia or hyperphosphatemia in hemodialysis patients. Moreover, stringent management of hypercalcemia and hyperphosphatemia in patients with a history of ACVD or DN might be associated with a better prognosis. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

19. Time to remission of proteinuria and incidence of relapse in patients with steroid-sensitive minimal change disease and focal segmental glomerulosclerosis: the Japan Nephrotic Syndrome Cohort Study

Author

Yamamoto, Ryohei, Imai, Enyu, Maruyama, Shoichi, Yokoyama, Hitoshi, Sugiyama, Hitoshi, Takeda, Asami, Tsukamoto, Tatsuo, Uchida, Shunya, Tsuruya, Kazuhiko, Shoji, Tatsuya, Hayashi, Hiroki, Akai, Yasuhiro, Fukunaga, Megumu, Konta, Tsuneo, Nishio, Saori, Goto, Shunsuke, Tamai, Hirofumi, Nagai, Kojiro, Katafuchi, Ritsuko, Masutani, Kosuke, Wada, Takashi, Nishino, Tomoya, Shirasaki, Arimasa, Sobajima, Hiroshi, Nitta, Kosaku, Yamagata, Kunihiro, Kazama, Junichiro J., Hiromura, Keiju, Yasuda, Hideo, Mizutani, Makoto, Akahori, Toshiyuki, Naruse, Tomohiko, Hiramatsu, Takeyuki, Morozumi, Kunio, Mimura, Tetsushi, Saka, Yosuke, Ishimura, Eiji, Hasegawa, Hajime, Ichikawa, Daisuke, Shigematsu, Takashi, Sato, Hiroshi, Narita, Ichiei, and Isaka, Yoshitaka

Published
2022
Full Text
View/download PDF

21. Predictors of early remission of proteinuria in adult patients with minimal change disease: a retrospective cohort study

Author

Yamamoto, Ryohei, Imai, Enyu, Maruyama, Shoichi, Yokoyama, Hitoshi, Sugiyama, Hitoshi, Takeda, Asami, Uchida, Shunya, Tsukamoto, Tatsuo, Tsuruya, Kazuhiko, Akai, Yasuhiro, Nitta, Kosaku, Fukunaga, Megumu, Hayashi, Hiroki, Masutani, Kosuke, Wada, Takashi, Konta, Tsuneo, Katafuchi, Ritsuko, Nishio, Saori, Goto, Shunsuke, Tamai, Hirofumi, Shirasaki, Arimasa, Shoji, Tatsuya, Nagai, Kojiro, Nishino, Tomoya, Yamagata, Kunihiro, Kazama, Junichiro J., Hiromura, Keiju, Yasuda, Hideo, Mizutani, Makoto, Naruse, Tomohiko, Hiramatsu, Takeyuki, Morozumi, Kunio, Sobajima, Hiroshi, Saka, Yosuke, Ishimura, Eiji, Ichikawa, Daisuke, Shigematsu, Takashi, Sofue, Tadashi, Fujimoto, Shouichi, Ito, Takafumi, Sato, Hiroshi, Narita, Ichiei, and Isaka, Yoshitaka

Published
2022
Full Text
View/download PDF

25. The benefit of reduced serum phosphate levels depends on patient characteristics: a nationwide prospective cohort study.

Author

Goto, Shunsuke, Hamano, Takayuki, Fujii, Hideki, Taniguchi, Masatomo, Abe, Masanori, Nitta, Kosaku, and Nishi, Shinichi

Subjects
*OLDER patients, *DIABETIC nephropathies, *HEMODIALYSIS patients, *RENAL osteodystrophy, CARDIOVASCULAR disease related mortality
Abstract

Background In cohort studies of hyperphosphatemic hemodialysis patients, reduced serum phosphate levels have been linked to a lower mortality risk. To investigate whether this benefit is influenced by patient characteristics, we calculated the number needed to be exposed (NNE), stratified by patient characteristics. Methods In this 9-year prospective cohort study using the nationwide Japanese registry, we enrolled 78 256 hemodialysis patients aged 18 years or older. We investigated the relationship between time-averaged (TA) phosphate levels and mortality due to cardiovascular disease (CVD) using Cox proportional models. We estimated the 1-year NNE for CVD death in patients with baseline serum phosphate levels ≥6.0 mg/dL and exposure to TA phosphate levels decreasing to 3.5–<5.0 mg/dL using mixed-effects Poisson models. Results The hazard ratio of CVD mortality decreased linearly with lower serum TA phosphate levels in those with prior atherosclerotic CVD (ACVD) or diabetic nephropathy (DN) but plateaued with serum phosphate <5.0 mg/dL in those without. The hazard ratios (95% confidence interval) for phosphate ≥7.0 mg/dL compared with 3.5–<3.9 mg/dL were 1.58 (1.38–1.81) in those with prior ACVD, 1.91 (1.68–2.17) in those without, 1.87 (1.63–2.16) in those with DN and 1.65 (1.46–1.87) in those without. However, the NNE for one more person to benefit (NNEB) for CVD death was lower in patients with a history of ACVD than in those without (61 vs 118). Patients with DN had lower NNEB than those without (69 vs 113). In patients with TA albumin ≥3.8 g/dL, older patients had lower NNEB, while patients with TA albumin <3.45 g/dL showed no benefit in some groups, including the elderly. Conclusions The benefit of intensive phosphate management may be pronounced in patients with a history of ACVD or DN. A comprehensive approach that considers both age and nutritional status may be necessary when managing serum phosphate levels. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Better remission rates in elderly Japanese patients with primary membranous nephropathy in nationwide real-world practice: The Japan Nephrotic Syndrome Cohort Study (JNSCS)

Author

Yokoyama, Hitoshi, Yamamoto, Ryohei, Imai, Enyu, Maruyama, Shoichi, Sugiyama, Hitoshi, Nitta, Kosaku, Tsukamoto, Tatsuo, Uchida, Shunya, Takeda, Asami, Sato, Toshinobu, Wada, Takashi, Hayashi, Hiroki, Akai, Yasuhiro, Fukunaga, Megumu, Tsuruya, Kazuhiko, Masutani, Kosuke, Konta, Tsuneo, Shoji, Tatsuya, Hiramatsu, Takeyuki, Goto, Shunsuke, Tamai, Hirofumi, Nishio, Saori, Shirasaki, Arimasa, Nagai, Kojiro, Yamagata, Kunihiro, Hasegawa, Hajime, Yasuda, Hidemo, Ichida, Shizunori, Naruse, Tomohiko, Fukami, Kei, Nishino, Tomoya, Sobajima, Hiroshi, Tanaka, Satoshi, Akahori, Toshiyuki, Ito, Takafumi, Terada, Yoshio, Katafuchi, Ritsuko, Fujimoto, Shouichi, Okada, Hirokazu, Ishimura, Eiji, Kazama, Junichiro James, Hiromura, Keiju, Mimura, Tetsushi, Suzuki, Satashi, Saka, Yosuke, Sofue, Tadashi, Suzuki, Yusuke, Shibagaki, Yugo, Kitagawa, Kiyoki, Morozumi, Kunio, Fujita, Yoshiro, Mizutani, Makoto, Shigematsu, Takashi, Furuichi, Kengo, Fujimoto, Keiji, Kashihara, Naoki, Sato, Hiroshi, Matsuo, Seiichi, Narita, Ichiei, and Isaka, Yoshitaka

Published
2020
Full Text
View/download PDF

32. Incidence of remission and relapse of proteinuria, end-stage kidney disease, mortality, and major outcomes in primary nephrotic syndrome: the Japan Nephrotic Syndrome Cohort Study (JNSCS)

Author

Yamamoto, Ryohei, Imai, Enyu, Maruyama, Shoichi, Yokoyama, Hitoshi, Sugiyama, Hitoshi, Nitta, Kosaku, Tsukamoto, Tatsuo, Uchida, Shunya, Takeda, Asami, Sato, Toshinobu, Wada, Takashi, Hayashi, Hiroki, Akai, Yasuhiro, Fukunaga, Megumu, Tsuruya, Kazuhiko, Masutani, Kosuke, Konta, Tsuneo, Shoji, Tatsuya, Hiramatsu, Takeyuki, Goto, Shunsuke, Tamai, Hirofumi, Nishio, Saori, Shirasaki, Arimasa, Nagai, Kojiro, Yamagata, Kunihiro, Hasegawa, Hajime, Yasuda, Hideo, Ichida, Shizunori, Naruse, Tomohiko, Nishino, Tomoya, Sobajima, Hiroshi, Tanaka, Satoshi, Akahori, Toshiyuki, Ito, Takafumi, Terada, Yoshio, Katafuchi, Ritsuko, Fujimoto, Shouichi, Okada, Hirokazu, Ishimura, Eiji, Kazama, Junichiro J., Hiromura, Keiju, Mimura, Tetsushi, Suzuki, Satoshi, Saka, Yosuke, Sofue, Tadashi, Suzuki, Yusuke, Shibagaki, Yugo, Kitagawa, Kiyoki, Morozumi, Kunio, Fujita, Yoshiro, Mizutani, Makoto, Shigematsu, Takashi, Kashihara, Naoki, Sato, Hiroshi, Matsuo, Seiichi, Narita, Ichiei, and Isaka, Yoshitaka

Published
2020
Full Text
View/download PDF

33. Salvage robot‐assisted radical prostatectomy after carbon ion radiotherapy to the prostate

Author

Shiota, Masaki, primary, Tsukahara, Shigehiro, additional, Takamatsu, Dai, additional, Tanegashima, Tokiyoshi, additional, Ueda, Shohei, additional, Blas, Leandro, additional, Goto, Shunsuke, additional, Kobayashi, Satoshi, additional, Matsumoto, Takashi, additional, Inokuchi, Junichi, additional, Shioyama, Yoshiyuki, additional, and Eto, Masatoshi, additional

Published
2024
Full Text
View/download PDF

46. Hypocalcemia and cardiovascular mortality in cinacalcet users.

Author

Goto, Shunsuke, Hamano, Takayuki, Fujii, Hideki, Taniguchi, Masatomo, Abe, Masanori, Nitta, Kosaku, and Nishi, Shinichi

Subjects
*HYPOCALCEMIA, *MYOCARDIAL ischemia, *CORONARY disease, *SUDDEN death, CARDIOVASCULAR disease related mortality
Abstract

Background Calcimimetics are widely used in hemodialysis patients and influence serum calcium levels. Although the Kidney Disease: Improving Global Outcomes guidelines argued that low calcium levels induced by calcimimetics may be harmless, large observational studies investigating the association between hypocalcemia and mortality are scarce. We investigated the association between serum calcium levels and cardiovascular mortality in calcimimetics users using the nationwide Japanese registry for dialysis patients. Methods In this 9-year prospective cohort study, the baseline data were collected at the end of 2009. We enrolled patients on maintenance hemodialysis or hemodiafiltration. We employed three models (baseline, time-dependent and time-averaged) to conduct Cox proportional hazard regression analyses. Results Cinacalcet was prescribed to 12.7% (N  = 22 853) at baseline. The median observation period was 98 (interquartile range 40–108) months and 108 (interquartile range 59–108) months in the whole cohort (N  = 180 136) and in cinacalcet users, respectively. Three-quarters of survivors at the end of 2019 had continued calcimimetic therapy for 10 years, corresponding to a mean annual dropout rate of 2.9%. Hypocalcemia was not associated with cardiovascular mortality in the baseline or time-averaged model. In the time-dependent model, however, the lowest calcium decile (corrected calcium <8.4 mg/dL) was significantly associated with higher cardiovascular mortality than the reference (corrected calcium 8.7–8.9 mg/dL) in both cinacalcet users and all patients [hazard ratio (95% confidence interval) 1.32 (1.00, 1.75) and 1.15 (1.05, 1.26), respectively]. Hypocalcemia was especially associated with sudden death and death due to hemorrhagic stroke, heart failure and ischemic heart disease. Higher rate of fatal and non-fatal cardiovascular events was observed in hypocalcemic patients regardless of cinacalcet usage. Conclusions Our findings suggest that transient hypocalcemia was associated with an increased risk of cardiovascular death independent of cinacalcet usage. We should pay attention to hypocalcemia transiently induced by cinacalcet. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

47. Validation of schedules for optimal prostate‐specific antigen monitoring after radical prostatectomy.

Author

Blas, Leandro, Shiota, Masaki, Tanegashima, Tokiyoshi, Tsukahara, Shigehiro, Ueda, Shohei, Mutaguchi, Jun, Goto, Shunsuke, Kobayashi, Satoshi, Matsumoto, Takashi, Inokuchi, Junichi, and Eto, Masatoshi

Subjects
PROSTATE-specific antigen, RADICAL prostatectomy, CANCER hospitals, SURVIVAL rate, GLEASON grading system
Abstract

Background: Early detection of biochemical recurrence (BCR) after radical prostatectomy (RP) is crucial for early treatment and improving survival outcomes. The optimal prostate‐specific antigen (PSA) monitoring remains unclear, and several models have been proposed. We aimed to externally validate four models for optimal PSA monitoring after RP and propose modifications to improve them. Methods: We reviewed the clinicopathological data of 896 patients who underwent robot‐assisted RP between 2009 and 2022. We examined all PSA values and estimated the PSA value for four monitoring schedules at each time point in the virtual follow‐up. We defined the ideal PSA for BCR detection between 0.2 and 0.4 ng/mL. Results: During the median follow‐up of 21.4 months, 128 (14.3%) patients presented BCR. The original and modified Keio models, National Cancer Center Hospital model, and American Urological Association/American Society for Radiation Oncology model detected BCR in 14 (10.9%), three (2.3%), 12 (9.4%), and 11 (8.6%) patients with PSA >0.4 ng/mL. Most patients experienced BCR detected with PSA >0.4 ng/mL during the first year postoperative. The modification of interval within 6 months postoperative avoided BCR detection with PSA >0.4 ng/mL within the first year postoperative in 8/9 (88.9%), 1/2 (50.0%), 5/6 (83.3%), and 4/4 (100%) for the original and modified Keio models, National Cancer Center Hospital model, and American Urological Association/American Society for Radiation Oncology model, respectively. Conclusion: We validated four models for PSA monitoring after RP to detect BCR and suggested modifications to avoid detections out of the desired range of PSA. These modifications could help to establish an optimal PSA monitoring schedule after RP. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

49. Regional variations in immunosuppressive therapy in patients with primary nephrotic syndrome: the Japan nephrotic syndrome cohort study

Author

Yamamoto, Ryohei, Imai, Enyu, Maruyama, Shoichi, Yokoyama, Hitoshi, Sugiyama, Hitoshi, Nitta, Kosaku, Tsukamoto, Tatsuo, Uchida, Shunya, Takeda, Asami, Sato, Toshinobu, Wada, Takashi, Hayashi, Hiroki, Akai, Yasuhiro, Fukunaga, Megumu, Tsuruya, Kazuhiko, Masutani, Kosuke, Konta, Tsuneo, Shoji, Tatsuya, Hiramatsu, Takeyuki, Goto, Shunsuke, Tamai, Hirofumi, Nishio, Saori, Shirasaki, Arimasa, Nagai, Kojiro, Yamagata, Kunihiro, Hasegawa, Hajime, Yasuda, Hidemo, Ichida, Shizunori, Naruse, Tomohiko, Fukami, Kei, Nishino, Tomoya, Sobajima, Hiroshi, Tanaka, Satoshi, Akahori, Toshiyuki, Ito, Takafumi, Yoshio, Terada, Katafuchi, Ritsuko, Fujimoto, Shouichi, Okada, Hirokazu, Ishimura, Eiji, Kazama, Junichiro James, Hiromura, Keiju, Mimura, Tetsushi, Suzuki, Satashi, Saka, Yosuke, Sofue, Tadashi, Suzuki, Yusuke, Shibagaki, Yugo, Kitagawa, Kiyoki, Morozumi, Kunio, Fujita, Yoshiro, Mizutani, Makoto, Shigematsu, Takashi, Kashihara, Naoki, Sato, Hiroshi, Matsuo, Seiichi, Narita, Ichiei, and Isaka, Yoshitaka

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results